Cationic Tripeptides Target Non-Enveloped Virus Infections

Solution Overview

Problem

Current treatments for non-enveloped virus infections, such as rhinovirus, rotavirus, and human papillomavirus, are limited due to the resistance of these viruses to existing antiviral agents and the lack of effective disinfectants, leading to significant healthcare challenges.

Innovation Solution

Development of cationic and bulky tripeptide compounds, specifically compounds like LTX-109 and LTX-7, which exhibit excellent antiviral activity against non-enveloped viruses by targeting negatively charged regions on the viral surface, potentially reducing the risk of resistance development.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional antiviral agents are used against non-enveloped viruses, then treatment options are limited, but viral resistance develops reducing effectiveness

Engineering Contradiction:

Improveeffectiveness of antiviral treatmentVSAvoidviral resistance

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The invention changes the chemical parameters of antiviral agents by using cationic tripeptide structures with specific amino acid compositions (two cationic amino acids and one amino acid with large lipophilic R group) and C-terminal modifications. This parameter change creates a new class of antivirals that work through electrostatic attraction to negatively charged viral surfaces, bypassing the resistance mechanisms that have developed against conventional agents like pleconaril

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The invention creates composite molecular structures combining multiple amino acid residues with specific properties (cationic charges, lipophilic groups) and C-terminal modifications into a unified tripeptide framework. This composite structure enables simultaneous electrostatic interaction and hydrophobic binding to viral surfaces, creating a multi-mechanism antiviral agent that overcomes single-mechanism resistance

Inventive Principle:

Principle #40Composite materials

2Object-affected harmful factors

If non-enveloped viruses are targeted with existing disinfectants, then virus resistance occurs, but effective disinfectant options remain scarce

Engineering Contradiction:

Improvevirus resistance to disinfectantsVSAvoidnumber of effective agents

Core Design Contradiction:

Object-affected harmful factorsVSQuantity of substance

Solution Approach 1:

The invention changes the chemical parameters of antiviral agents by using cationic tripeptide structures with specific amino acid compositions (two cationic amino acids and one amino acid with large lipophilic R group) and C-terminal modifications. This parameter change creates a new class of antivirals that work through electrostatic attraction to negatively charged viral surfaces, bypassing the resistance mechanisms that have developed against conventional agents like pleconaril

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The cationic tripeptide structure demonstrates universal antiviral activity across multiple non-enveloped virus types (rhinovirus, rotavirus, HPV) through a common mechanism of electrostatic attraction to negatively charged viral surfaces. This multi-functional capability expands the number of effective agents available for treating diverse non-enveloped virus infections

Inventive Principle:

Principle #6Universality (Multi-functionality)

3Reliability

If enveloped virus treatments are applied to non-enveloped viruses, then treatment efficacy is reduced, but non-enveloped viruses lack the fragile lipid envelope

Engineering Contradiction:

Improvetreatment efficacyVSAvoidviral structure

Core Design Contradiction:

ReliabilityVSShape

Solution Approach 1:

The invention changes the chemical parameters of antiviral agents by using cationic tripeptide structures with specific amino acid compositions (two cationic amino acids and one amino acid with large lipophilic R group) and C-terminal modifications. This parameter change creates a new class of antivirals that work through electrostatic attraction to negatively charged viral surfaces, bypassing the resistance mechanisms that have developed against conventional agents like pleconaril

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The invention applies local quality by designing tripeptides with specific functional groups positioned at particular locations: cationic amino acids for electrostatic interaction with negatively charged viral surfaces, and amino acids with large lipophilic R groups for hydrophobic interactions with specific viral surface regions. This localized functional distribution optimizes binding to non-enveloped virus structures

Inventive Principle:

Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

These compounds demonstrate a significant reduction in virus infectivity, with LTX-109 showing a 99% reduction in Rhinovirus 60 infectivity and LTX-7 showing at least a 90% reduction, indicating their effectiveness as potential therapeutic agents for non-enveloped virus infections.

Implementation Method 1

cationic (positively charged) and bulky... targeting negatively charged regions on the viral surface

Methodology Applied

Scientific EffectElectrostatic attraction: Electrostatics

Data Source

PatentUS20240390451A1Modified tripeptides for use in the treatment of a non-enveloped virus infection

Publication Date: 2024.11.28 PHARM HLDG AS

AI summary

The invention described herein relates to modified tripeptides, in particular LTX-109, for use in the treatment of non-enveloped virus infections.